Viking Therapeutics advances obesity drug pipeline aiming for $1.3B sales by 2030 with unique dual agonist approach.

Viking Therapeutics is progressing well with its obesity drug pipeline, focusing on a unique dual agonist treatment in a competitive market dominated by Lilly and Novo Nordisk. The company targets capturing 5–10% of the market through global expansion and late-stage development, with Phase 3 trials for its oral drug VK2735 expected by late 2026. Commercial launch is anticipated in 2028, potentially generating $1.3 billion in sales by 2030. Despite concerns over cash burn, investor confidence remains strong, with consistent buying since April 2025 indicating optimism about the company's growth prospects.